Arrowhead Subsidiary, Insert Therapeutics, to Present at Institutional Investor Conference.PASADENA, Calif. -- Arrowhead Research Corporation (Nasdaq:ARWR) announced today that Edward Jacobs, Chief Executive Officer and President of Insert Therapeutics, a majority-owned subsidiary majority-owned subsidiary A firm in which more than 50% of outstanding voting stock is owned by the parent company. of Arrowhead, will present at the May 18th Annual Institutional Investor Institutional Investor A non-bank person or organization that trades securities in large enough share quantities or dollar amounts that they qualify for preferential treatment and lower commissions. Conference at the Princeton Club The Princeton Club of New York is a social organization in New York City catering to faculty and alumni of Princeton University in Princeton, New Jersey. Incorporated on Dec. 7, 1899, the club has had four homes before settling into its current clubhouse at 15 W. in New York City New York City: see New York, city. New York City City (pop., 2000: 8,008,278), southeastern New York, at the mouth of the Hudson River. The largest city in the U.S. on May 22, 2007. Mr. Jacobs' presentation, entitled "Insert Therapeutics Product Development Update," will highlight Insert's progress in using its proprietary polymeric transport system, Cyclosert(TM), to design, develop and commercialize nanoparticle-enhanced small-molecule therapeutics. Insert's lead drug candidate, a combination of its linear, cyclodextrin-based polymer and the anti-cancer compound camptothecin, entered the clinic in 2006. Mr. Jacobs has been the Chief Executive Officer of Insert Therapeutics since January 2007. Prior to joining Insert, he held CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. positions at a number of life science companies and has more than 20 years of executive level pharma and biotech experience, with particular emphasis in the oncology space, as well as strategic planning and marketing. He has successfully led several biotech companies to acquisition by major pharmaceutical companies and secured substantial collaborations and licensing deals. About Arrowhead Research Corporation Arrowhead Research Corporation (www.arrowheadresearch.com) is a publicly-traded nanotechnology company commercializing new technologies in the areas of life sciences, electronics, and energy. Arrowhead is building value for shareholders through the progress of majority-owned subsidiaries founded on nanotechnologies originally developed at universities. The company works closely with universities to source early stage deals and to generate rights to intellectual property covering promising new nanotechnologies. Currently, Arrowhead has four subsidiaries commercializing nanotech products and applications, including anti-cancer drugs, RNAi therapeutics, carbon-based electronics and compound semiconductor materials. About Insert Therapeutics Insert Therapeutics, Inc. (www.insertt.com), a majority-owned subsidiary of Arrowhead Research Corporation (NASDAQ:ARWR), is using its proprietary, nano-engineered, polymeric delivery system, Cyclosert(TM), to design, develop and commercialize drug-delivery-enhanced small-molecule therapeutics and nucleic acids Nucleic acids The cellular molecules DNA and RNA that act as coded instructions for the production of proteins and are copied for transmission of inherited traits. . Cyclosert uses cyclodextrins as building blocks to create an entirely new class of biocompatible materials - linear cyclodextrin-containing polymers that are non-toxic and non-immunogenic at therapeutic doses. Insert's affiliate company, Calando ca·lan·do adv. & adj. Music With a gradual decrease in volume and often tempo. Used chiefly as a direction. [Italian, present participle of calare, to slacken Pharmaceuticals, is using a related system for the systemic delivery of siRNA. The companies are pursuing this goal through internal research and development, and also through collaborations and partnerships with pharmaceutical and biotechnology companies. Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. Statement under the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995: This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies, the future success of our scientific studies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. and 10-K/A, recent and forthcoming Quarterly Reports on Form 10-Q Form 10-Q See 10-Q. and 10-Q/A, recent Current Reports on Forms 8-K and 8-K/A, our Registration Statements on Form S-3, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion